Kashiv BioSciences

Kashiv BioSciences is a vertically integrated biopharmaceutical company established in 2015, specializing in the development and manufacturing of biosimilars and complex generic medicines. With over 500 employees and significant manufacturing infrastructure in the US and India, the company has a robust pipeline of 8+ programs and has achieved key regulatory milestones, including BLA/MAA submissions for its lead biosimilar candidate. The company's strategy is built on a fully integrated model from R&D to fill/finish, aiming to accelerate development, ensure quality, and reduce costs to improve global access to biologics. Recent financing and strategic partnerships, such as with Intas Pharmaceuticals and JAMP Pharma, underscore its growth trajectory and commercial execution capabilities.

Vertically integrated development and manufacturing platform for biologics and complex generics, encompassing end-to-end capabilities from R&D and clinical development through to fill/finish manufacturing.

Kashiv competes in the biosimilar space against large, established generics companies (e.g., Sandoz, Viatris, Biocon) and dedicated biosimilar firms (e.g., Coherus, Celltrion). Its vertical integration is a key differentiator against pure-play developers, but it faces competition on cost, speed to market, and commercial muscle from larger players with broader portfolios.